Objectives: Harmonization of prostate-specific antigen (PSA) immunoassays is important for good patient care. The specificity of the antibodies used to detect circulating PSA could cause differences in the PSA measurements.
Prostate-specific antigen (PSA) measurements are used to screen men for prostate cancer and to monitor treatment of prostate disease. The role of PSA for screening is controversial because some studies show that the potential harm is greater than the benefits. 1 However, PSA tests still are widely used, and there is a need to harmonize test results to ensure that consistent levels are used for medical decisions. The best way to harmonize test results is to make the measurement systems traceable to reference systems. 2 This has been difficult for PSA because the commercial immunoassays use different antibodies that may react differently to various circulating forms of PSA. Mass spectrometry (MS) measurement of selected peptides derived from trypsin digestion of PSA could provide a traceable method for harmonizing PSA immunoassays if PSA is immune-extracted prior to digestion and an appropriate peptide is selected. This study provides background investigations for the development of such an assay.
PSA is a 34-kDa glycoprotein that circulates in blood as both free forms and forms complexed to various enzyme inhibitors, including antichymotrypsin (ACT) and a 2 -macroglobulin (A2M). PSA bound to A2M is not detected by commercial PSA immunoassays. There also are circulating homologs of PSA that may cross-react with PSA immunoassays. Human glandular kallikrein 2 (hK2) is a PSA homolog with 79% identity in amino acid sequences that circulates at concentrations 30-to 80-fold lower than PSA. 3 There also may be circulating precursor forms and degradation products of PSA that could cause differences between PSA assays. Differences in the immune reactivity of the antibodies used in the immunoassays potentially could cause some assays to detect some of these circulating forms, while other assays may not detect them.
The PSA molecule has 237 amino acids arranged in a three-dimensional structure with a glycosylation site at position 45 and a cleavage site that inactivates enzymatic activity at positions 145 and 146. 4 For simplicity, the linear sequences of PSA and the hK2 molecule are illustrated in ❚Figure 1❚. The PSA molecule has six major epitopes that have threedimensional binding, but for simplicity, these epitopes are illustrated to map to approximately the linear regions shown in the figure. 5, 6 Standardization of PSA immunoassays has been problematic because of the differences between the two reference materials used to calibrate the assays. Initially, most of the assays were calibrated to the Hybritech calibrator (Beckman Coulter, Chaska, MN). However, now many assays are calibrated with the World Health Organization (WHO) 96/670 standard, which gives results 20% to 25% lower. [7] [8] [9] Even when assays are calibrated with the same reference material, they may give different results for patient samples. MS measurement of peptides made from trypsin digestion of large proteins is a valuable tool for investigating differences in protein immunoassays. For biomarkers having both intact molecules and degradation products or isoforms of the molecules found in blood, one peptide may be present in all forms, whereas another peptide may be present only in the intact form. Comparison of MS quantitation of the concentration of multiple peptides with the immunoassay measurements may help to demonstrate the causes for immunoassay differences.
In this study, we used MS to quantitate the concentration of five unique peptides cleaved from trypsin-digested PSA. As noted above, a special issue with PSA is the existence of circulating A2M-complexed PSA, which does not bind to the antibodies used in commercial PSA assays; however, this complexed form would be detected by MS. To overcome this difficulty, we immune-extracted the PSA from the samples prior to MS. We used five monoclonal antibodies that have been mapped to different epitopes on the PSA molecule (see shaded boxes in Figure 1 ). The immune-extracted proteins were trypsin digested, and five of the digestion peptides were quantitated on MS. As illustrated by the dark boxes in Figure 1 , these five peptide regions were selected to cover different parts of the PSA molecule that are not subject to ❚Figure 1❚ Amino acid sequence of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2). The open boxes show PSA epitopes. The dark boxes show the position of the five peptides, and the shaded boxes show the approximate binding areas of the extraction antibodies. MS, mass spectrometry. glycosylation. A panel of 14 specimens consisting of serumbased standards, controls, and pools and a WHO standard set at 10 ng/mL were measured in replicate on six commercial immunoassays and with the peptide-based MS quantitations. The five extraction antibodies used in this study are the same antibodies used in several of the immunoassays. The MS measurements were normalized to provide complete recovery of the WHO 96/670 PSA standard. The MS measurement data were analyzed to determine the effects of the peptides used for quantitation on the harmonization of the MS results with the results from each immunoassay.
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Materials and Methods
Panel of Specimens
Seven calibrators were made by adding the PSA/ACT Complex (catalog No. P0625; Scripps Laboratories, San Diego, CA) and recombinant human kallikrein 3 (catalog No. 1344-SE; R&D Systems, Minneapolis, MN) to female serum from a single donor (Solomon Park Research Laboratories, Kirkland, WA). A target of approximately 90% complexed and 10% free PSA was achieved by adding the PSA/ACT and enzymatically inactive recombinant PSA into the female serum to a target level of 80 ng/mL. Five twofold serial dilutions were performed with the female sera to make six calibrators plus a zero. Seven controls were included in the panel. Three commercial controls were purchased from CLINIQA (San Marcos, CA) with approximate values of 2, 15, and 30 ng/mL. In addition, four serum controls were made from deidentified patient serum: pool 1B is from men without known prostate cancer, and pools 2C, 3C, and 4C are from men with biopsy-proven prostate cancer with various levels of PSA. The panel also included a WHO international reference standard PSA (90:10; code, 96/670), purchased from National Institute for Biological Standards and Control (Hertfordshire, England). This standard was diluted to a PSA value of 10 ng/mL in phosphate-buffered saline (PBS) with 0.1% bovine serum albumin. Aliquots (500 mL) of each of these panel members were frozen at -80°C. The calibrators and the WHO standard were made from pure PSA and complexes, so they do not include precursor forms or degradation products of PSA and do not incorporate PSA homologs; however, the pools and controls probably contain these potential cross-reactants.
Immunoassay Measurement of Panel
The panel was measured in triplicate on 3 separate days using six commercial immunoassays: (1) Beckman Coulter (Brea, CA) Access 2, (2) Siemens (Erlangen, Germany) Advia Centaur XP, (3) Abbott (Abbott Park, IL) Architect, (4) Roche (Basel, Switzerland) cobas E601, (5) Siemens DPC Immulite 2000, and (6) Ortho (Victoria, Australia) Vitros Eci/ EciQ. The Abbott and Ortho measurements were performed at the companies' laboratories, while the others were measured in house.
Immune Extraction of PSA
Five monoclonal antibodies used in the PSA immunoassays were obtained from suppliers of commercial PSA reagents: (1) PSA10 and (2) PSA36 from Fujirebio Diagnostics (Malvern, PA), (3) H50 and (4) H117 from Abbott Laboratories, and (5) PSM773 from Beckman Coulter. These antibodies were labeled with biotin to facilitate coupling to magnetic beads. We used the protocol from the Pierce Sulfo-NHS-LC-Biotin kit, the Pierce Biotin Quantitation Kit, and Zeba Desalt Column. These reagents were purchased from Thermo Scientific (Rockford, IL). The antibodies and 20-fold molar excess of biotin were incubated for 1 hour at room temperature with occasional vortexing. The unbound biotin was removed by buffer exchange into 100 mmol/L PBS (pH 7.4) using the Zeba Desalt Column. The biotin-labeled antibodies were immobilized to 1 mL Dynabeads M-280 streptavidin superparamagnetic beads (Life Technologies, Grand Island, NY). The beads were washed three times with 100 mmol/L PBS (pH 7.4) to remove any storage buffer. The biotin-labeled antibody was added and mixed for 60 minutes, rotating at room temperature. After incubation, the beads were washed three times with 100 mmol/L PBS with 0.01% Zwittergent (EMD Millipore, Darmstadt, Germany) using a magnetic separator. Beads were treated with 5% acidic acid for a 5-minute rotation at room temperature to remove any nonspecific bound proteins and washed three times with 100 mmol/L PBS with 0.01% Zwittergent. The immune extraction of PSA used 400 mL of serum mixed with 2 to 10 mg of antibodies per 100 mL of magnetic beads. The volume of samples was adjusted to 800 mL with PBS containing 0.01% Zwittergent for overnight incubation at 4°C on a rotator. Using a magnetic separator, the unbound fraction was removed and stored. The beads were washed two times with 100 µL PBS containing 0.01% Zwittergent, transferred to a new tube, and washed a third time, leaving the beads to dry after the final wash in preparation for the trypsin digest.
Trypsin Digestion of PSA Extracts
All digests were performed with extracted PSA bound to magnetic beads on a shaker at 1,400 rotations per minute. Samples were denatured with 20 mL of 6 mol/L urea and reduced with 30 mmol/L dithiothreitol for 1 hour at 60°C on a shaker. Samples were alkylated with iodoacetamide at a concentration of 60 mmol/L for 45 minutes in the dark at room temperature on a shaker. After reduction and alkylation, the samples were diluted to 100 mL with 50 mmol/L NH 4 HCO 3 (pH 8) to lower the urea concentration to 1.2 mol/L, and 1 mg of trypsin was added for a 4-hour digestion at 37°C on a shaker. Reaction was stopped with 2 mL of formic acid, and the supernatant containing the peptides of interest was recovered on a magnetic separator.
Peptides and Stable Isotope-Labeled Peptide Internal Standards
Computer-simulated trypsin digestion of PSA was performed to identify potential peptides. Then a quadruple time-of-flight mass spectrometer (Q-TOF Premier, Waters, Milford, MA) was used to identify and acquire the relative abundance of the tryptic peptides of interest generated from the digestion of recombinant PSA. Five tryptic peptides-FLRPGDDSSHDLMLLR (FLR), FMLCAGR (FML), HSQP-WQVLVASR (HSQ), IVGGWECEK (IVG), and LSEPAELT-DAVK (LSE)-were selected to measure multiple-reaction monitoring transitions. The sequences of four peptides (FLR, FML, HSQ, and LSE) were specific to PSA (P07288 KLK3_ HUMAN), suggesting that these sequences could be used to specifically quantify PSA. The IVG peptide shares the same sequence with hK2, as shown in Figure 1 .
The stable isotope peptides were synthesized in the Mayo Proteomics Research Center (Rochester, MN) on an ACT 396 Multiple Peptide Synthesizer (Advanced ChemTech, Louisville, KY). For LSE, the double-charged precursor ion was 639.9 2+ , and single-charge transitions of 949.5 and 475.4 were monitored. For IVG, the double-charged precursor ion was 543.9 2+ with single-charge transitions of 868.4 and 973.6. For HSQ, the double-charged ion was 707.6, with single-charge transitions of 1,061.9 and 778.4. For FLR, the triple-charged precursor ion was 628.6 3+ , and single-charge transitions of 652.6 and 767.5 were monitored. For FML, the double-charged precursor ion was 433.1 2+ , and single-charge transitions of 586.4 and 466.6 were monitored. For IVG and FML, the Cys-containing internal standard peptides were alkylated during peptide synthesis.
Prior to adding the stable isotopes to the digested samples, they were premixed in the following composition: 20 ng/mL of each FML, IVG, and LSE peptide and 200 ng/mL of each FLR and HSQ peptide. Each injection had 0.2 ng of each FML, IVG, and LSE peptide and 2 ng of each FLR and HSQ peptide. These concentrations were chosen to maintain the signal response from stable isotopes in the same range as the signal response from corresponding native peptides.
Liquid Chromatography-Tandem MS
Absolute quantitation was performed by liquid chromatography-tandem MS (MS/MS) using a CTC Analytics HTC PAL autosampler (LEAP Technologies, Carrboro, NC), a Shimadzu 10-AD binary pumping system (Shimadzu Scientific Instruments, Columbia, MD), and an API 5000 triple-quadruple mass spectrometer (Applied Biosystems, Foster City, CA). For each run, a total of 100 mL of sample was injected onto a 50 × 2.1-mm TARGA C 18 column (Higgins Analytical, Mountain View, CA) and run at 250 mL/ min for 30 minutes. The gradient used consisted of solvent A (water, 0.1% formic acid) and solvent B (methanol, 0.1% formic acid) starting at 5% B for 2 minutes, ramping to 95% B over 22 minutes, holding at 95% B for 2 minutes, back to 5% B in 1 minute, and then holding to 30 minutes. The following transitions were used: FLR = 625.05/760.4, FML = 427.7/463.21, HSQ = 703.6/772.5, IVG = 539.54/964.4, and LSE = 636.8/472.37. All samples were run twice on 2 different days using a new standard curve and quality control (QC) for each set. The batch for each set of samples contained seven standards, six QCs in the beginning, two QCs in the middle, and six QCs at the end of the run.
Statistical Methods
Means and coefficients of variation (CVs) were calculated for the replicate immunoassay values and the MS peptide values. For the MS summary table, the five immune extraction antibodies were averaged for each quantitated peptide. Linear regression was used to compare each immunoassay with the other immunoassays and with the five MS peptide quantitations. For each of the 13 specimens (excluding the WHO standard), PSA immunoassay results were expressed as a percentage of the MS/MS quantitation for each peptide, antibody, and assay combination. Mixed-effects models were then fit (for each assay) to model percentage error as a function of antibody and peptide effects using SAS software (SAS Institute, Cary, NC).
Results
The upper part of ❚Table 1❚ shows the means and CVs of the immunoassay measurements. All immunoassays had CVs less than 8%, with most CVs in the range of 2% to 4%. There were substantial differences in the recovery of the WHO standard, with the Siemens Advia and Roche cobas underrecovering by 5% to 6% and the others overrecovering by 8% to 18%. Each immunoassay was calibrated to the WHO 96/670 standard except the Beckman Coulter Access 2, which was calibrated to the Hybritech calibrator. As predicted by these calibrator differences, the Beckman Coulter Access 2 assay produced higher values than the other assays; however, if these values were adjusted down by 20%, they would be lower than the WHO standard. The lower part of Table 1 shows the linear regression slopes comparing the immunoassays. The Beckman Coulter Access 2 assay produced higher values than the other assays; however, the values were only 2% to 11% higher. Overall, among the immunoassays, the Beckman Coulter Access 2 and Siemens Immulite had the highest values. The Roche cobas and Siemens Advia had the lowest values, while the Abbott Architect and Ortho Vitros had intermediate values.
❚Table 2❚ shows the means, CVs, and regression data for the MS peptide assays. The CVs were much higher than the immunoassay CVs, especially for samples with lower concentrations. The LSE peptide assay had the lowest CVs, with values of 2% to 6% except for the two samples with concentrations less than 2 ng/mL. It is interesting to note that the PSA concentrations in pools 1B through 4C are very similar for each of the five peptide methods. This suggests that there are not substantial amounts of circulating PSA precursors or PSA fragments that contain one peptide but not the other peptides. The lower part of Table 2 shows the linear regression slopes comparing each immunoassay on the vertical y-axis with each of the five peptide-based MS assays on the horizontal x-axis. The standard errors of the slopes show that the relative errors of the slopes are about 1% to 3%. The relationships between the immunoassay results and the MS concentrations based on each peptide are similar to the between-immunoassay comparisons shown in Table 1 . The Beckman Coulter Access 2 and Siemens Immulite had the highest values. The Roche cobas and Siemens Advia had the lowest values, while the Abbott Architect and Ortho Vitros had intermediate values. Table 2 shows the corresponding MS peptide measurements and their correlations with the immunoassays. The SAS mixed-effects models found strong peptide effects (all P < .001) for all assays with minimal antibody effects (P = .03-.18). ❚Table 3❚ shows percentage errors and interquartile ranges for comparing each peptide assay with each immunoassay combining the 65 observations (13 samples measured with the five extraction antibodies). The LSE peptide had the best results across all six immunoassays. In examining the effects of assay and antibody for the LSE peptide, there was no interaction of assay-antibody, but there was a small antibody effect and a large assay effect. The Advia, cobas, and Vitros had least squares means (adjusted for antibody) for percent error that were not significantly different from zero. This again implies that PSA immunoassay differences are more related to calibration differences than specificity of the antibodies for detecting different PSA forms.
Discussion
This study shows that the test results for all immunoassays and our MS peptide assays for PSA are highly correlated, but the concentration values differ even when the assays are calibrated using the same reference standard. The recovery of the WHO reference standard diluted in PBS differed among the immunoassays, and these recoveries generally were in concordance with the regression slopes for the immunoassay comparisons. It is important to note that comparisons among the assays of the calibrators in our panel made with purified PSA and PSA complexes added to female serum compared very similarly with the endogenous serum pools from men. These male specimens could contain various precursor forms and degradation products of PSA. The similarity of these comparisons suggests that these alternate PSA forms do not contribute substantially to the lack of harmonization of PSA immunoassays. This finding may be caused by the low antibody cross-reactivity with these forms or the low concentration of these forms. The major issue with PSA harmonization appears to be related to assay calibration. These calibration differences may be related to poor commutability of the buffer-based reference materials and the patient specimens. In addition, these calibration differences could be caused by the different value assignment procedures used by various manufacturers or the uncertainty of the value assignments for the calibrators.
Various investigators have demonstrated differences in measuring PSA with automated immunoassays. [10] [11] [12] [13] [14] A 2006 study from the Netherlands compared six automated immunoassays using serum pools and the WHO 96/670. 10 Ortho Vitros with serum. They found the highest value with the Immulite and Access 2 and lower values with the Advia, Architect, and cobas, similar to our findings. In evaluating the WHO standard, they found the highest values with the Access 2 (slope = 1.22), followed by the Architect (slope = 1.06). The Advia, cobas, and Immulite all had similar slopes, with values between 0.99 and 1.01. These measurements of the WHO material are similar to our data except for the Immulite, which gave high values similar to the Access 2. However, the standardization of the instruments may have changed over the multiyear interval between studies, and the United States may be different from Europe.
A study from Utah also compared serum samples on six automated immunoassays but included the Beckman Coulter DxI800 rather than the Beckman Coulter Access 2. 11 The Immulite had the highest slope at 1.164, followed by the Vitros at 1.143 and the DxI800 at 1.078. The cobas and Advia had lower values with slopes of 0.976 and 0.836, respectively. This study noted that the Vitros and DxI800 were calibrated to a "purified PSA standard" rather than the WHO 96/670.
The authors of a recent (2012) Irish study compared six immunoassays in different laboratories using serum samples. 12 Their Beckman Coulter Access was WHO calibrated, and they used the Siemens Immulite 2500 and Abbott AxSym along with the cobas and Advia. The methods were coded and compared with the Beckman Access. Each method gave higher results, with increases varying from 9% to 28%. A German study compared five instruments in 2006 using serum samples, 14 including the Access, Immulite, Advia, Abbott AxSym, and Roche Elecsys 2012. In comparison with the Beckman Access, Immulite had the highest slope (1.15), and the slopes with the other assays were as follows: Elecsys (1.01), Advia (0.87), and AxSym (0.87). It was not clear how these assays were standardized.
Although our study used only a small number of specimens, the good precision of the immunoassay replicates and the strong correlations among methods, along with the consistency of our between-assay-level differences with those found by others, indicate that current PSA immunoassays are not well harmonized. The major cause of the between-assay differences does not appear to be the specificity of the antibodies used in the immunoassays because the same betweenassay differences are found with MS assays based on peptides cleaved from different parts of the PSA molecule. This study suggests that PSA immunoassays can be harmonized if the calibration differences could be resolved, potentially by making them traceable to an MS peptide assay using trypsindigested immune-extracted PSA.
